Main results of reported gout management in Brazil
| Proportion (%) | |
|---|---|
| Target serum uric acid (SUA) level for a patient with no tophi: <6 mg/dl | 70.0 |
| Target SUA level for a patient with tophi: <6 mg/dl | 78.9 |
| Urate-lowering therapy (ULT) dose unchanged during acute gout | 67.0 |
| Always or almost always prophylactic treatment is prescribed when initiating ULT | 92.4 |
| Duration of prophylaxis for patients with no tophi | |
| ≤6 months | 59.3 |
| until they reach the target SUA level | 20.0 |
| Indefinitely | 9.8 |
| Duration of prophylaxis for patients with tophi | |
| ≤6 months | 28.5 |
| until they reach the target SUA level | 13.9 |
| Indefinitely | 34.6 |
| Initial dose of allopurinol 50 or 100mg/day for patients with ClCr | |
| >60 ml/min | 51.3 |
| ≤60 ml/min | 91.0 |
| ULT kept indefinitely after achieving target SUA level in a patient | |
| without tophi | 39.6 |
| with tophi | 76.3 |